...
首页> 外文期刊>Nanomaterials >Synthesis, Characterization, and Nanomedical Applications of Conjugates between Resorcinarene-Dendrimers and Ibuprofen
【24h】

Synthesis, Characterization, and Nanomedical Applications of Conjugates between Resorcinarene-Dendrimers and Ibuprofen

机译:间苯二烯-树枝状聚合物和布洛芬之间的结合物的合成,表征和纳米医学应用

获取原文

摘要

Ibuprofen has been reported to possess anticancer activity. In the present work, four ibuprofen conjugates of resorcinarene-Polyamidoamine PAMAM-dendrimers were synthesized with eight or 16 ibuprofen moieties. The ibuprofen was released from the dendrimers in a dependent manner. The drug-conjugated nanoresorcinarene-dendrimers showed higher cellular uptake than free ibuprofen. In vitro cytotoxicity studies were performed with free ibuprofen and with the synthesized conjugates in U251, PC-3, K-562, HCT-15, MCF-7, SKLU-1, and MDA U251 (human glioblastoma), PC-3 (human prostatic adenocarcinoma), K-562 (human chronic myelogenous leukemia cells), HCT-15 (human colorectal adenocarcinoma), MCF-7 (human mammary adenocarcinoma), SKLU-1 (human lung adenocarcinoma), and MDA-MB-231 (human mammary adenocarcinoma) cancer cell lines by different cytotoxicity assays. Ibuprofen conjugates of the first and second generations showed significant cytotoxic effects towards the human glioblastoma (U251) and human mammary adenocarcinoma (MCF-7, MDA) cell lines. Moreover, the ibuprofen conjugates improved cytotoxicity compared to free ibuprofen. Increased therapeutic efficacy was observed with specific ibuprofen conjugates of the second generation using low doses.
机译:据报道布洛芬具有抗癌活性。在目前的工作中,合成了具有8或16个布洛芬部分的间苯二芳基-聚酰胺酰胺PAMAM-树枝状大分子的四个布洛芬缀合物。布洛芬以依赖性方式从树状聚合物中释放。药物偶联的纳米间苯二酚-树状大分子显示出比游离布洛芬更高的细胞摄取。用游离布洛芬和合成的结合物在U251,PC-3,K-562,HCT-15,MCF-7,SKLU-1和MDA U251(人成胶质细胞瘤),PC-3(人)中进行体外细胞毒性研究前列腺腺癌),K-562(人类慢性粒细胞白血病细胞),HCT-15(人类结直肠腺癌),MCF-7(人类乳腺腺癌),SKLU-1(人类肺腺癌)和MDA-MB-231(人类乳腺腺癌)癌细胞系通过不同的细胞毒性测定。第一和第二代布洛芬缀合物对人胶质母细胞瘤(U251)和人乳腺腺癌(MCF-7,MDA)细胞系显示出显着的细胞毒性作用。此外,与游离布洛芬相比,布洛芬缀合物改善了细胞毒性。使用低剂量的第二代特定布洛芬偶联物观察到治疗效果提高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号